Open AccessApplication of advanced brain positron emission tomography–based molecular imaging for a biological framework in neurodegenerative proteinopathies
Author(s) -
Perani Daniela,
Iaccarino Leonardo,
Jacobs Andreas H.,
Lammertsma Adriaan A.,
Nordberg Agneta,
Windhorst Albert D.,
Gerhard Alexander,
Winkeler Alexandra,
Jacobs Andreas H.,
Gee Anthony,
Kuhnast Bertrand,
Halldin Christer,
Perani Daniela,
Brooks David,
RodriguezVieitez Elena,
Turkheimer Federico E.,
LópezPicón Francisco,
Knudsen Gitte M.,
Vercouillie Johnny,
Rinne Juha O.,
Herholz Karl,
Van Laere Koen,
Varrone Andrea,
SantiagoRibeiro Marie Joao,
Herth Matthias M.,
Carroll Michael A.,
Chalon Sylvie,
Bottlaender Michel,
Hansson Oskar,
Edison Paul,
Hinz Rainer,
Boellaard Ronald,
Moresco Rosa Maria,
Pappata Sabina
Publication year - 2019
Publication title -
alzheimer's and dementia: diagnosis, assessment and disease monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.497
H-Index - 37
ISSN - 2352-8729
DOI - 10.1016/j.dadm.2019.02.004
Subject(s) - positron emission tomography , neurodegeneration , neuroscience , dementia , molecular imaging , neuroimaging , neuroinformatics , medical physics , medicine , disease , pathology , psychology , biology , microbiology and biotechnology , in vivo
A rapid transition from a clinical‐based classification to a pathology‐based classification of neurodegenerative conditions, largely promoted by the increasing availability of imaging biomarkers, is emerging. The Framework for Innovative Multi‐tracer molecular Brain Imaging, funded by the EU Joint Program ‐ Neurodegenerative Disease Research 2016 “Working Groups for Harmonisation and Alignment in Brain Imaging Methods for Neurodegeneration,” aimed at providing a roadmap for the applications of established and new molecular imaging techniques in dementia. Methods We consider current and future implications of adopting a pathology‐based framework for the use and development of positron emission tomography techniques. Results This approach will enhance efforts to understand the multifactorial etiology of Alzheimer's disease and other dementias. Discussion The availability of pathology biomarkers will soon transform clinical and research practice. Crucially, a comprehensive understanding of strengths and caveats of these techniques will promote an informed use to take full advantage of these tools.